APO Research
Talk to an analyst

APO RESEARCH · REPORT

Antihemophilic Factor Drug

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Antihemophilic Factor Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

20 December 2025197 pages

Choose your research edition.

Industry ResearchAntihemophilic Factor Drug Industry Research Report 2026125 pages · $2,950 USDIndustry Growth & TrendsGlobal Antihemophilic Factor Drug Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Antihemophilic Factor Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Antihemophilic Factor Drug Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Antihemophilic Factor Drug Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Antihemophilic Factor Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Antihemophilic Factor Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Antihemophilic Factor Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Antihemophilic Factor Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Antihemophilic Factor Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Antihemophilic Factor Drug include Cigna, CSL Behring, GC Pharma, Grifols, Octapharma, Bayer, Hualan Biological Engineering, Pfizer and Novo Nordisk, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Antihemophilic Factor Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Antihemophilic Factor Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Antihemophilic Factor Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Antihemophilic Factor Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Antihemophilic Factor Drug Segment by Company

Cigna

CSL Behring

GC Pharma

Grifols

Octapharma

Bayer

Hualan Biological Engineering

Pfizer

Novo Nordisk

Sanofi

Shanghai RAAS blood products

Takeda

Antihemophilic Factor Drug Segment by Type

250 IU

500 IU

1000 IU

1500 IU

2000 IU

3000 IU

4000 IU

Other potencies

Antihemophilic Factor Drug Segment by Application

Adult

Pediatric

Antihemophilic Factor Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antihemophilic Factor Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Antihemophilic Factor Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antihemophilic Factor Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Antihemophilic Factor Drug market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Antihemophilic Factor Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Antihemophilic Factor Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Antihemophilic Factor Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Antihemophilic Factor Drug Industry Trends Table 2. Antihemophilic Factor Drug Industry Drivers Table 3. Antihemophilic Factor Drug Industry Opportunities and Challenges Table 4. Antihemophilic Factor Drug Industry Restraints Table 5. Global Antihemophilic Factor Drug Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Antihemophilic Factor Drug Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Antihemophilic Factor Drug Sales by Manufacturers (W Units) & (2021-2026) Table 8. Global Antihemophilic Factor Drug Sales Market Share by Manufacturers Table 9. Global Antihemophilic Factor Drug Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Antihemophilic Factor Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Antihemophilic Factor Drug Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Antihemophilic Factor Drug Manufacturers, Product Type & Application Table 13. Global Antihemophilic Factor Drug Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Antihemophilic Factor Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of 250 IU Table 17. Major Manufacturers of 500 IU Table 18. Major Manufacturers of 1000 IU Table 19. Major Manufacturers of 1500 IU Table 20. Major Manufacturers of 2000 IU Table 21. Major Manufacturers of 3000 IU Table 22. Major Manufacturers of 4000 IU Table 23. Major Manufacturers of Other potencies Table 24. Global Antihemophilic Factor Drug Sales by Type 2021 VS 2025 VS 2032 (W Units) Table 25. Global Antihemophilic Factor Drug Sales by Type (2021-2026) & (W Units) Table 26. Global Antihemophilic Factor Drug Sales by Type (2027-2032) & (W Units) Table 27. Global Antihemophilic Factor Drug Sales Market Share by Type (2021-2026) Table 28. Global Antihemophilic Factor Drug Sales Market Share by Type (2027-2032) Table 29. Global Antihemophilic Factor Drug Revenue by Type 2021 VS 2025 VS 2032 (W Units) Table 30. Global Antihemophilic Factor Drug Revenue by Type (2021-2026) & (W Units) Table 31. Global Antihemophilic Factor Drug Revenue by Type (2027-2032) & (W Units) Table 32. Global Antihemophilic Factor Drug Revenue Market Share by Type (2021-2026) Table 33. Global Antihemophilic Factor Drug Revenue Market Share by Type (2027-2032) Table 34. Major Manufacturers of Adult Table 35. Major Manufacturers of Pediatric Table 36. Global Antihemophilic Factor Drug Sales by Application 2021 VS 2025 VS 2032 (W Units) Table 37. Global Antihemophilic Factor Drug Sales by Application (2021-2026) & (W Units) Table 38. Global Antihemophilic Factor Drug Sales by Application (2027-2032) & (W Units) Table 39. Global Antihemophilic Factor Drug Sales Market Share by Application (2021-2026) Table 40. Global Antihemophilic Factor Drug Sales Market Share by Application (2027-2032) Table 41. Global Antihemophilic Factor Drug Revenue by Application 2021 VS 2025 VS 2032 (W Units) Table 42. Global Antihemophilic Factor Drug Revenue by Application (2021-2026) & (W Units) Table 43. Global Antihemophilic Factor Drug Revenue by Application (2027-2032) & (W Units) Table 44. Global Antihemophilic Factor Drug Revenue Market Share by Application (2021-2026) Table 45. Global Antihemophilic Factor Drug Revenue Market Share by Application (2027-2032) Table 46. Global Antihemophilic Factor Drug Sales by Region: 2021 VS 2025 VS 2032 (W Units) Table 47. Global Antihemophilic Factor Drug Sales by Region (2021-2026) & (W Units) Table 48. Global Antihemophilic Factor Drug Sales Market Share by Region (2021-2026) Table 49. Global Antihemophilic Factor Drug Sales Forecasted by Region (2027-2032) & (W Units) Table 50. Global Antihemophilic Factor Drug Sales Forecasted Market Share by Region (2027-2032) Table 51. North America Antihemophilic Factor Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 52. North America Antihemophilic Factor Drug Sales by Country (2021-2026) & (W Units) Table 53. North America Antihemophilic Factor Drug Sales by Country (2027-2032) & (W Units) Table 54. Europe Antihemophilic Factor Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 55. Europe Antihemophilic Factor Drug Sales by Country (2021-2026) & (W Units) Table 56. Europe Antihemophilic Factor Drug Sales by Country (2027-2032) & (W Units) Table 57. Asia Pacific Antihemophilic Factor Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 58. Asia Pacific Antihemophilic Factor Drug Sales by Country (2021-2026) & (W Units) Table 59. Asia Pacific Antihemophilic Factor Drug Sales by Country (2027-2032) & (W Units) Table 60. South America, Middle East and Africa Antihemophilic Factor Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 61. South America, Middle East and Africa Antihemophilic Factor Drug Sales by Country (2021-2026) & (W Units) Table 62. South America, Middle East and Africa Antihemophilic Factor Drug Sales by Country (2027-2032) & (W Units) Table 63. Global Antihemophilic Factor Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 64. Global Antihemophilic Factor Drug Revenue by Region (2021-2026) & (US$ Million) Table 65. Global Antihemophilic Factor Drug Revenue by Region (2027-2032) & (US$ Million) Table 66. Global Antihemophilic Factor Drug Revenue Market Share by Region (2021-2026) Table 67. Global Antihemophilic Factor Drug Revenue Market Share by Region (2027-2032) Table 68. Cigna Company Information Table 69. Cigna Business Overview Table 70. Cigna Antihemophilic Factor Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Cigna Antihemophilic Factor Drug Product Portfolio Table 72. Cigna Recent Development Table 73. CSL Behring Company Information Table 74. CSL Behring Business Overview Table 75. CSL Behring Antihemophilic Factor Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. CSL Behring Antihemophilic Factor Drug Product Portfolio Table 77. CSL Behring Recent Development Table 78. GC Pharma Company Information Table 79. GC Pharma Business Overview Table 80. GC Pharma Antihemophilic Factor Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. GC Pharma Antihemophilic Factor Drug Product Portfolio Table 82. GC Pharma Recent Development Table 83. Grifols Company Information Table 84. Grifols Business Overview Table 85. Grifols Antihemophilic Factor Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Grifols Antihemophilic Factor Drug Product Portfolio Table 87. Grifols Recent Development Table 88. Octapharma Company Information Table 89. Octapharma Business Overview Table 90. Octapharma Antihemophilic Factor Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. Octapharma Antihemophilic Factor Drug Product Portfolio Table 92. Octapharma Recent Development Table 93. Bayer Company Information Table 94. Bayer Business Overview Table 95. Bayer Antihemophilic Factor Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 96. Bayer Antihemophilic Factor Drug Product Portfolio Table 97. Bayer Recent Development Table 98. Hualan Biological Engineering Company Information Table 99. Hualan Biological Engineering Business Overview Table 100. Hualan Biological Engineering Antihemophilic Factor Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 101. Hualan Biological Engineering Antihemophilic Factor Drug Product Portfolio Table 102. Hualan Biological Engineering Recent Development Table 103. Pfizer Company Information Table 104. Pfizer Business Overview Table 105. Pfizer Antihemophilic Factor Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 106. Pfizer Antihemophilic Factor Drug Product Portfolio Table 107. Pfizer Recent Development Table 108. Novo Nordisk Company Information Table 109. Novo Nordisk Business Overview Table 110. Novo Nordisk Antihemophilic Factor Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 111. Novo Nordisk Antihemophilic Factor Drug Product Portfolio Table 112. Novo Nordisk Recent Development Table 113. Sanofi Company Information Table 114. Sanofi Business Overview Table 115. Sanofi Antihemophilic Factor Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 116. Sanofi Antihemophilic Factor Drug Product Portfolio Table 117. Sanofi Recent Development Table 118. Shanghai RAAS blood products Company Information Table 119. Shanghai RAAS blood products Business Overview Table 120. Shanghai RAAS blood products Antihemophilic Factor Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 121. Shanghai RAAS blood products Antihemophilic Factor Drug Product Portfolio Table 122. Shanghai RAAS blood products Recent Development Table 123. Takeda Company Information Table 124. Takeda Business Overview Table 125. Takeda Antihemophilic Factor Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 126. Takeda Antihemophilic Factor Drug Product Portfolio Table 127. Takeda Recent Development Table 128. Key Raw Materials Table 129. Raw Materials Key Suppliers Table 130. Antihemophilic Factor Drug Distributors List Table 131. Antihemophilic Factor Drug Customers List Table 132. Research Programs/Design for This Report Table 133. Authors List of This Report Table 134. Secondary Sources Table 135. Primary Sources List of Figures Figure 1. Antihemophilic Factor Drug Product Image Figure 2. Global Antihemophilic Factor Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Antihemophilic Factor Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Antihemophilic Factor Drug Sales (2021-2032) & (W Units) Figure 5. Global Antihemophilic Factor Drug Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Antihemophilic Factor Drug Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. 250 IU Image Figure 9. 500 IU Image Figure 10. 1000 IU Image Figure 11. 1500 IU Image Figure 12. 2000 IU Image Figure 13. 3000 IU Image Figure 14. 4000 IU Image Figure 15. Other potencies Image Figure 16. Global Antihemophilic Factor Drug Sales by Type (2021 VS 2025 VS 2032) & (W Units) Figure 17. Global Antihemophilic Factor Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 18. Global Antihemophilic Factor Drug Sales Market Share by Type (2021-2032) Figure 19. Global Antihemophilic Factor Drug Revenue by Type (2021 VS 2025 VS 2032) & (W Units) Figure 20. Global Antihemophilic Factor Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 21. Global Antihemophilic Factor Drug Revenue Market Share by Type (2021-2032) Figure 22. Adult Image Figure 23. Pediatric Image Figure 24. Global Antihemophilic Factor Drug Sales by Application (2021 VS 2025 VS 2032) & (W Units) Figure 25. Global Antihemophilic Factor Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 26. Global Antihemophilic Factor Drug Sales Market Share by Application (2021-2032) Figure 27. Global Antihemophilic Factor Drug Revenue by Application (2021 VS 2025 VS 2032) & (W Units) Figure 28. Global Antihemophilic Factor Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 29. Global Antihemophilic Factor Drug Revenue Market Share by Application (2021-2032) Figure 30. North America Antihemophilic Factor Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 31. North America Antihemophilic Factor Drug Sales Market Share by Country (2021-2032) Figure 32. U.S. Antihemophilic Factor Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 33. Canada Antihemophilic Factor Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 34. Mexico Antihemophilic Factor Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 35. Europe Antihemophilic Factor Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 36. Europe Antihemophilic Factor Drug Sales Market Share by Country (2021-2032) Figure 37. Germany Antihemophilic Factor Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 38. France Antihemophilic Factor Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 39. U.K. Antihemophilic Factor Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 40. Italy Antihemophilic Factor Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 41. Netherlands Antihemophilic Factor Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 42. Asia Pacific Antihemophilic Factor Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 43. Asia Pacific Antihemophilic Factor Drug Sales Market Share by Country (2021-2032) Figure 44. China Antihemophilic Factor Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 45. Japan Antihemophilic Factor Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 46. South Korea Antihemophilic Factor Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 47. Southeast Asia Antihemophilic Factor Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 48. India Antihemophilic Factor Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 49. Australia Antihemophilic Factor Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 50. South America, Middle East and Africa Antihemophilic Factor Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 51. South America, Middle East and Africa Antihemophilic Factor Drug Sales Market Share by Country (2021-2032) Figure 52. Brazil Antihemophilic Factor Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 53. South Africa Antihemophilic Factor Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 54. Saudi Arabia Antihemophilic Factor Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 55. Turkey Antihemophilic Factor Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 56. Argentina Antihemophilic Factor Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 57. UAE Antihemophilic Factor Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 58. Egypt Antihemophilic Factor Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 59. Chile Antihemophilic Factor Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 60. Global Antihemophilic Factor Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 61. Global Antihemophilic Factor Drug Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 62. North America Antihemophilic Factor Drug Revenue (2021-2032) & (US$ Million) Figure 63. North America Antihemophilic Factor Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Europe Antihemophilic Factor Drug Revenue (2021-2032) & (US$ Million) Figure 65. Europe Antihemophilic Factor Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Asia-Pacific Antihemophilic Factor Drug Revenue (2021-2032) & (US$ Million) Figure 67. Asia-Pacific Antihemophilic Factor Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. South America, Middle East and Africa Antihemophilic Factor Drug Revenue (2021-2032) & (US$ Million) Figure 69. South America, Middle East and Africa Antihemophilic Factor Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 70. Antihemophilic Factor Drug Value Chain Figure 71. Manufacturing Cost Structure Figure 72. Antihemophilic Factor Drug Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. Years Considered Figure 76. Research Process Figure 77. Key Executives Interviewed

Scope & coverage.

Types
  • 250 IU
  • 500 IU
  • 1000 IU
  • 1500 IU
  • 2000 IU
  • 3000 IU
  • 4000 IU
  • Other potencies
Applications
  • Adult
  • Pediatric
Companies covered
  • Cigna
  • CSL Behring
  • GC Pharma
  • Grifols
  • Octapharma
  • Bayer
  • Hualan Biological Engineering
  • Pfizer
  • Novo Nordisk
  • Sanofi
  • Shanghai RAAS blood products
  • Takeda

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Antihemophilic Factor Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Antihemophilic Factor Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Antihemophilic Factor Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Antihemophilic Factor Drug Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Antihemophilic Factor Drug Market Dynamics
  1. 2.1 Antihemophilic Factor Drug Industry Trends
  2. 2.2 Antihemophilic Factor Drug Industry Drivers
  3. 2.3 Antihemophilic Factor Drug Industry Opportunities and Challenges
  4. 2.4 Antihemophilic Factor Drug Industry Restraints
3 Antihemophilic Factor Drug Market by Manufacturers
  1. 3.1 Global Antihemophilic Factor Drug Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Antihemophilic Factor Drug Sales by Manufacturers (2021-2026)
  3. 3.3 Global Antihemophilic Factor Drug Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Antihemophilic Factor Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Antihemophilic Factor Drug Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Antihemophilic Factor Drug Manufacturers, Product Type & Application
  7. 3.7 Global Antihemophilic Factor Drug Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Antihemophilic Factor Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Antihemophilic Factor Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Antihemophilic Factor Drug Tier 1, Tier 2, and Tier 3
4 Antihemophilic Factor Drug Market by Type
  1. 4.1 Antihemophilic Factor Drug Type Introduction
  2. 4.1.1 250 IU
  3. 4.1.2 500 IU
  4. 4.1.3 1000 IU
  5. 4.1.4 1500 IU
  6. 4.1.5 2000 IU
  7. 4.1.6 3000 IU
  8. 4.1.7 4000 IU
  9. 4.1.8 Other potencies
  10. 4.2 Global Antihemophilic Factor Drug Sales by Type
  11. 4.2.1 Global Antihemophilic Factor Drug Sales by Type (2021 VS 2025 VS 2032)
  12. 4.2.2 Global Antihemophilic Factor Drug Sales by Type (2021-2032)
  13. 4.2.3 Global Antihemophilic Factor Drug Sales Market Share by Type (2021-2032)
  14. 4.3 Global Antihemophilic Factor Drug Revenue by Type
  15. 4.3.1 Global Antihemophilic Factor Drug Revenue by Type (2021 VS 2025 VS 2032)
  16. 4.3.2 Global Antihemophilic Factor Drug Revenue by Type (2021-2032)
  17. 4.3.3 Global Antihemophilic Factor Drug Revenue Market Share by Type (2021-2032)
5 Antihemophilic Factor Drug Market by Application
  1. 5.1 Antihemophilic Factor Drug Application Introduction
  2. 5.1.1 Adult
  3. 5.1.2 Pediatric
  4. 5.2 Global Antihemophilic Factor Drug Sales by Application
  5. 5.2.1 Global Antihemophilic Factor Drug Sales by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Antihemophilic Factor Drug Sales by Application (2021-2032)
  7. 5.2.3 Global Antihemophilic Factor Drug Sales Market Share by Application (2021-2032)
  8. 5.3 Global Antihemophilic Factor Drug Revenue by Application
  9. 5.3.1 Global Antihemophilic Factor Drug Revenue by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Antihemophilic Factor Drug Revenue by Application (2021-2032)
  11. 5.3.3 Global Antihemophilic Factor Drug Revenue Market Share by Application (2021-2032)
6 Global Antihemophilic Factor Drug Sales by Region
  1. 6.1 Global Antihemophilic Factor Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Antihemophilic Factor Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Antihemophilic Factor Drug Sales by Region (2021-2026)
  4. 6.2.2 Global Antihemophilic Factor Drug Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Antihemophilic Factor Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Antihemophilic Factor Drug Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Antihemophilic Factor Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Antihemophilic Factor Drug Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Antihemophilic Factor Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Antihemophilic Factor Drug Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Antihemophilic Factor Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Antihemophilic Factor Drug Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Antihemophilic Factor Drug Revenue by Region
  1. 7.1 Global Antihemophilic Factor Drug Revenue by Region
  2. 7.1.1 Global Antihemophilic Factor Drug Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Antihemophilic Factor Drug Revenue by Region (2021-2026)
  4. 7.1.3 Global Antihemophilic Factor Drug Revenue by Region (2027-2032)
  5. 7.1.4 Global Antihemophilic Factor Drug Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Antihemophilic Factor Drug Revenue (2021-2032)
  8. 7.2.2 North America Antihemophilic Factor Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Antihemophilic Factor Drug Revenue (2021-2032)
  11. 7.3.2 Europe Antihemophilic Factor Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Antihemophilic Factor Drug Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Antihemophilic Factor Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Antihemophilic Factor Drug Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Antihemophilic Factor Drug Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Cigna
  2. 8.1.1 Cigna Company Information
  3. 8.1.2 Cigna Business Overview
  4. 8.1.3 Cigna Antihemophilic Factor Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Cigna Antihemophilic Factor Drug Product Portfolio
  6. 8.1.5 Cigna Recent Developments
  7. 8.2 CSL Behring
  8. 8.2.1 CSL Behring Company Information
  9. 8.2.2 CSL Behring Business Overview
  10. 8.2.3 CSL Behring Antihemophilic Factor Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 CSL Behring Antihemophilic Factor Drug Product Portfolio
  12. 8.2.5 CSL Behring Recent Developments
  13. 8.3 GC Pharma
  14. 8.3.1 GC Pharma Company Information
  15. 8.3.2 GC Pharma Business Overview
  16. 8.3.3 GC Pharma Antihemophilic Factor Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 GC Pharma Antihemophilic Factor Drug Product Portfolio
  18. 8.3.5 GC Pharma Recent Developments
  19. 8.4 Grifols
  20. 8.4.1 Grifols Company Information
  21. 8.4.2 Grifols Business Overview
  22. 8.4.3 Grifols Antihemophilic Factor Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Grifols Antihemophilic Factor Drug Product Portfolio
  24. 8.4.5 Grifols Recent Developments
  25. 8.5 Octapharma
  26. 8.5.1 Octapharma Company Information
  27. 8.5.2 Octapharma Business Overview
  28. 8.5.3 Octapharma Antihemophilic Factor Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Octapharma Antihemophilic Factor Drug Product Portfolio
  30. 8.5.5 Octapharma Recent Developments
  31. 8.6 Bayer
  32. 8.6.1 Bayer Company Information
  33. 8.6.2 Bayer Business Overview
  34. 8.6.3 Bayer Antihemophilic Factor Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Bayer Antihemophilic Factor Drug Product Portfolio
  36. 8.6.5 Bayer Recent Developments
  37. 8.7 Hualan Biological Engineering
  38. 8.7.1 Hualan Biological Engineering Company Information
  39. 8.7.2 Hualan Biological Engineering Business Overview
  40. 8.7.3 Hualan Biological Engineering Antihemophilic Factor Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Hualan Biological Engineering Antihemophilic Factor Drug Product Portfolio
  42. 8.7.5 Hualan Biological Engineering Recent Developments
  43. 8.8 Pfizer
  44. 8.8.1 Pfizer Company Information
  45. 8.8.2 Pfizer Business Overview
  46. 8.8.3 Pfizer Antihemophilic Factor Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Pfizer Antihemophilic Factor Drug Product Portfolio
  48. 8.8.5 Pfizer Recent Developments
  49. 8.9 Novo Nordisk
  50. 8.9.1 Novo Nordisk Company Information
  51. 8.9.2 Novo Nordisk Business Overview
  52. 8.9.3 Novo Nordisk Antihemophilic Factor Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Novo Nordisk Antihemophilic Factor Drug Product Portfolio
  54. 8.9.5 Novo Nordisk Recent Developments
  55. 8.10 Sanofi
  56. 8.10.1 Sanofi Company Information
  57. 8.10.2 Sanofi Business Overview
  58. 8.10.3 Sanofi Antihemophilic Factor Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Sanofi Antihemophilic Factor Drug Product Portfolio
  60. 8.10.5 Sanofi Recent Developments
  61. 8.11 Shanghai RAAS blood products
  62. 8.11.1 Shanghai RAAS blood products Company Information
  63. 8.11.2 Shanghai RAAS blood products Business Overview
  64. 8.11.3 Shanghai RAAS blood products Antihemophilic Factor Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Shanghai RAAS blood products Antihemophilic Factor Drug Product Portfolio
  66. 8.11.5 Shanghai RAAS blood products Recent Developments
  67. 8.12 Takeda
  68. 8.12.1 Takeda Company Information
  69. 8.12.2 Takeda Business Overview
  70. 8.12.3 Takeda Antihemophilic Factor Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Takeda Antihemophilic Factor Drug Product Portfolio
  72. 8.12.5 Takeda Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Antihemophilic Factor Drug Value Chain Analysis
  2. 9.1.1 Antihemophilic Factor Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Antihemophilic Factor Drug Production Mode & Process
  6. 9.2 Antihemophilic Factor Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Antihemophilic Factor Drug Distributors
  9. 9.2.3 Antihemophilic Factor Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst